Skip to main content
NIH funding notice PAR-21-265

NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)

Closed on April 5, 2024.

Posted
July 15, 2021
Close date
April 5, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,481,525 in first-year total cost, median $740,763.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 HSS-J (10)]1
  2. Special Emphasis Panel[ZRG1 NV-C (10)]1

Most frequent institutions

  1. NOCTRIX HEALTH, INC1
  2. RHAEOS, INC.1
Competing awards under PAR-21-265 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families2R44NS121555-04SOMERA, ANNA LISARHAEOS, INC., IL$966,022ZRG1
2025Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome2R44NS117294-04CHARLESWORTH, JONATHAN DAVIDNOCTRIX HEALTH, INC, CA$515,503ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.